Nab-paclitaxel or docetaxel; as alternatives to conventional paclitaxel for the treatment of metastatic breast cancer (MBC): cost utility analysis from the perspective of the United Kingdom (UK)

✍ Scribed by G. Dranitsaris; M. Lidgren; J. Lundkvist; R. Coleman

• Book ID: 119597868
• Publisher: Elsevier Science
• Year: 2008
• Tongue: English
• Weight: 60 KB
• Volume: 6
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(08)70374-4